Author: Cazzola, Mario; Rogliani, Paola; Salvi, Sundeep Santosh; Ora, Josuel; Matera, Maria Gabriella
Title: Use of Thiols in the Treatment of COVID-19: Current Evidence Cord-id: m3wwcpcg Document date: 2021_8_27
ID: m3wwcpcg
Snippet: There is a possible role for oxidative stress, a state characterized by an altered balance between the production of free radicals or reactive oxygen species (ROS) and antioxidant defences, in coronavirus disease 2019 (COVID-19), the genesis of which is quite complex. Excessive oxidative stress could be responsible for the alveolar damage, thrombosis, and red blood cell dysregulation observed in COVID-19. Apparently, deficiency of glutathione (GSH), a low-molecular-weight thiol that is the most
Document: There is a possible role for oxidative stress, a state characterized by an altered balance between the production of free radicals or reactive oxygen species (ROS) and antioxidant defences, in coronavirus disease 2019 (COVID-19), the genesis of which is quite complex. Excessive oxidative stress could be responsible for the alveolar damage, thrombosis, and red blood cell dysregulation observed in COVID-19. Apparently, deficiency of glutathione (GSH), a low-molecular-weight thiol that is the most important non-enzymatic antioxidant molecule and has the potential to keep the cytokine storm in check, is a plausible explanation for the severe manifestations and death in COVID-19 patients. Thiol drugs, which are considered mucolytic, also possess potent antioxidant and anti-inflammatory properties. They exhibit antibacterial activity against a variety of medically important bacteria and may be an effective strategy against influenza virus infection. The importance of oxidative stress during COVID-19 and the various pharmacological characteristics of thiol-based drugs suggest a possible role of thiols in the treatment of COVID-19. Oral and intravenous GSH, as well as GSH precursors such as N-acetylcysteine (NAC), or drugs containing the thiol moiety (erdosteine) may represent a novel therapeutic approach to block NF-kB and address the cytokine storm syndrome and respiratory distress observed in COVID-19 pneumonia patients
Search related documents:
Co phrase search for related documents- ace activity and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9
- ace activity and additional treatment: 1
- ace activity inhibition and additional treatment: 1
- activation neutrophil and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- activation neutrophil and acute respiratory distress syndrome develop: 1
- active site and acute respiratory distress syndrome: 1, 2
- active site and additional study: 1, 2
- active site and adjunct therapy: 1
- active site and adjuvant therapy: 1, 2, 3
- acute respiratory distress syndrome and additional study: 1, 2, 3, 4, 5, 6, 7
- acute respiratory distress syndrome and additional therapy: 1, 2
- acute respiratory distress syndrome and additional treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory distress syndrome and adjunct therapy: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory distress syndrome and adjuvant therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome develop and additional study: 1, 2
- acute respiratory distress syndrome develop and additional treatment: 1
- acute respiratory distress syndrome develop and adjuvant therapy: 1, 2
- acute respiratory tract viral infection and adjuvant therapy: 1
- additional study and adjuvant therapy: 1, 2
Co phrase search for related documents, hyperlinks ordered by date